Absci (ABSI)

• Market cap: $395M
• 1 day: 2.99%
• 5 days: -1.27%
• 1 month: -30.80%
• 3 months: 2.99%
• 6 months: -21.72%
• Year to date: 14.39%
• 1 year: -38.74%
• 5 years: -85.64%
• 10 years: -85.64%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Employees: 157

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

121% more call options, than puts

Call options by funds: $850K | Put options by funds: $384K

55% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 22

27% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 33

7% more funds holding

Funds holding: 122 [Q3] → 131 (+9) [Q4]

0.52% more ownership

Funds ownership: 63.79% [Q3] → 64.31% (+0.52%) [Q4]

30% less capital invested

Capital invested by funds: $277M [Q3] → $194M (-$83.2M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 61% upside
• Avg. target: $7.75 150% upside
• High target: $10 223% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Guggenheim Vamil Divan 46% 1-year accuracy 12 / 26 met price target	223% upside $10	Buy Reiterated	20 Mar 2025
Needham Gil Blum 12% 1-year accuracy 19 / 159 met price target	190% upside $9	Buy Reiterated	19 Mar 2025
HC Wainwright & Co. Swayampakula Ramakanth 24% 1-year accuracy 48 / 198 met price target	126% upside $7	Buy Reiterated	19 Mar 2025
Keybanc Scott Schoenhaus 29% 1-year accuracy 9 / 31 met price target	61% upside $5	Overweight Maintained	8 Jan 2025